BCR and chronic myelogenous leukemia, BCR-ABL1 positive: ✓an inhibitor of PDGFR (IC50 = 100 nM), KIT (IC50 = 100 nM), and ABL1 (IC50 = 600 nM) [260]✓reduces BCR-ABL-mediated p-RPS6 (S235/236 and S240/244) via p70S6K inactivation in CML cells [86,102,103,104]✓upregulates PDCD4 in BCR-ABL CML cells but downregulates p-RPS6 (S235/236) and p-p70S6K (T389) [103]✓reduces p-RPS6 (S235/236) in the imatinib-sensitive CML cells but not in the imatinib-resistant cells [109]